Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
about
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerThe distinctive nature of adenocarcinoma of the lungNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesAdvances of heterogeneity of EGFR in non-small cell lung cancerGuide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerBlood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-AnalysisHigh-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingLiquid biopsy genotyping in lung cancer: ready for clinical utility?Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.Liquid biopsy: monitoring cancer-genetics in the blood.Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung CancerPrognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasPrevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancerThe Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer.The Exploration of Peptide Biomarkers in Malignant Pleural Effusion of Lung Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysisClinical trials and biomarker research on lung cancer in China.Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Liquid Biopsy in Non-Small Cell Lung Cancer.Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC.The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients.The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?
P2860
Q26769734-C89CEE2D-A718-40D1-AA37-387E4BD105E5Q26775376-81F509CD-2080-4F3C-83B6-7D2DB81AD9CEQ26781159-58527003-ACEA-40A3-8597-633B657BC2FFQ26801357-64DD91F4-1DC9-4726-9BE6-B4DD3BE84112Q26823978-6EC41972-6993-46E1-BC1E-3F57F77A30F0Q26999714-D3C25526-299B-42E4-88B2-11682526BEF8Q28079253-B0FE5E0E-DFC4-4C66-9B53-BEDB63FD9E38Q28082499-F721509C-2319-4E38-9A81-A230C5CE3658Q28087366-FD061905-099C-4C63-98DC-FCD19B871AE4Q30514084-8C2564E1-DD46-4004-BD33-8A618E8219E3Q33567037-7CA36527-C89B-410C-8390-757CAD03B6D2Q33582524-D1CDF0A5-FAB6-4256-ADFA-D704E9BEDDDBQ34092157-83478D45-CF3B-4184-BDA8-AB7D0405633EQ34350615-F638AA3B-02C6-434F-943B-F16C1956E434Q34356149-065798F8-10F6-40ED-A63C-CD793F91D4BEQ35038358-CA2FB83B-894E-4D83-9411-7CEC0536D283Q35654703-ED7137AB-3D58-430E-B1E2-2B8044820580Q35775729-06D79E41-9FFB-497C-83F9-1CCD3C5AF949Q36085837-1B5C2F2E-7360-43ED-BEFF-C795AD3C32E1Q36095650-7AF7043C-A6D0-472B-80B6-E8B4C5A44441Q36278010-646190E2-E598-42A0-A164-21F6D37182B1Q36339096-827AE96F-4C51-4E2A-B8EF-F3531E746E8EQ36544438-8726C292-92FE-4C7C-B210-12A1A8EE6332Q36666814-23669567-51F1-439C-BD2F-06C830F94FA6Q37114899-C7982E6A-A3D2-4804-8577-95F1524B2B3BQ37345952-A9E7C1B2-A30E-42A1-8264-9D040897C64BQ37592893-A3F64ED2-A2F0-4169-9A90-9BC02167C11DQ37690677-6E347B7C-9C52-4560-864A-A6419A070237Q37743832-4C525167-0E39-47F9-ACE9-0D8A28F54C3EQ37982119-45A94441-8256-4C10-A17B-F732CEF8C5C1Q38203956-F9ABBE70-9A0E-44DB-A3AF-65B234E501ADQ38263419-6F801F98-D1E6-47B2-8DA1-610716D774A0Q38844281-A6BF995B-E85C-4300-8D90-DC3ADE601CB3Q38903804-0F71B81D-D442-4030-B3B5-1C541E930232Q38988061-8B0AF326-61F8-4FF0-8CB7-B9351059F216Q39076207-577B2A4B-CB4E-4C7C-A988-C6AE28D71B10Q40494002-C6D9071C-5198-44A3-AF07-E185A27B075BQ41472736-80A32055-BD59-46DB-B810-425BDCF9F4C4Q41574578-D917B73D-0B89-4449-BFAA-10313C7A90B5Q41866575-6A9CE1A7-8C1C-4E06-945A-8F09FACAF797
P2860
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@ast
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@en
type
label
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@ast
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@en
prefLabel
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@ast
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@en
P2093
P2860
P1433
P1476
Detection of EGFR mutations in ...... nd response to EGFR inhibitors
@en
P2093
Christopher G Azzoli
Marie Brevet
Melissa L Johnson
P2860
P304
P356
10.1016/J.LUNGCAN.2010.10.014
P50
P577
2010-12-03T00:00:00Z